Skip to content

Impact of a LCD on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant Patients

Impact of a Low Carbohydrate Diet (LCD) on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant (LT) Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04145427
Enrollment
42
Registered
2019-10-30
Start date
2020-02-27
Completion date
2023-09-15
Last updated
2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight Gain

Keywords

Liver Transplant, Low Carbohydrate Diet

Brief summary

This study is looking to see how a 6-month low carbohydrate diet can affect the body's ability to use energy in addition to the affects it has on the heart and blood vessel health.

Detailed description

Weight gain often occurs following a liver transplant. This weight gain is problematic as it leads to many other health problems. The reasons of this weight gain are still poorly understood. To better understand weight gain, this study is looking to see how a 6-month low carbohydrate diet can affect the body's ability to use energy in addition to the affects it has on heart and blood vessel health. This study will help researchers to better understand weight gain after a transplant. This knowledge will help doctors prevent weight gain after a liver transplant and therefore improve the health of liver transplant patients.

Interventions

BEHAVIORALControl

Initial Weight Loss consultation 1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided. 4 lifestyle coaching sessions Monthly visits for behavioral and dietary coaching as well as medication management.

BEHAVIORALLCD

Initial Weight Loss consultation 1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided. 4 lifestyle coaching sessions Monthly visits for behavioral and dietary coaching as well as medication management.

Sponsors

Virginia Commonwealth University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * At least 12 months after LT * Obese (BMI \> 30kg/m2)

Exclusion criteria

* Acute cellular or chronic rejection within 3 months * Post-LT liver or non-liver related malignancy * Active viral hepatitis (B or C), autoimmune hepatitis * Untreated biliary strictures or vascular complications (i.e. hepatic artery thrombosis) * Poorly controlled Diabetes mellitus * Relapse of alcohol abuse after LT * Stage 5 Chronic Kidney Disease * Current pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in weightbaseline to 6 monthsWeight will be measured on a standardized scale in kilograms that will be zeroed out prior to the measurement

Secondary

MeasureTime frameDescription
Change in metabolic flexibilitybaseline to 6 monthsThis will be measured in whole room calorimeter and reported as respiratory quotient
Change in LDL-Cbaseline to 6 monthsLDL-cholesterol will be measured using a fasting blood draw and a standard lipid panel.
Change in total cholesterolbaseline to 6 monthsTotal cholesterol will be measured using a fasting blood draw and a standard lipid panel.
Change in small dense low-density lipoproteinbaseline to 6 monthsSmall dense LDL will be measured using a fasting blood draw and a standard lipid panel.
Change in adipositybaseline to 6 monthsThis will be measured on body composition MRI where subcutaneous and visceral fat will be quantified. Subcutaneous fat and visceral fat volume will measured on body composition MRI in liters (L) and standardized to body height and will be reported as liter/m2

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026